renal anemia
Conditions
Interventions
roxadustst 70mg or 100mg
Sponsors
Showa University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) PD patients who are treated at Showa university and HD patients who are treated at Shibagaki clinic. 2) Hemoglobin level above 9g/dL, and ferritin 100 ng/mL or TSAT>20%. 3) Patienta who are more than 20 year-old 4) Patients who are treated by ESA more than 3 months. 5) Patients who are provided written, informed consent to participate
Exclusion criteria
Exclusion criteria: 1) Patients who have history of allergy for HIF-PH inhibitor. 2) Patients who are taking HIF-PH inhibitor. 3) Patients whose serum ferritin level 100 ng/mL and TSAT<20%. 4) Pregnant women. 5) Patients with bleeding, severe liver disease, malignant, chronic infection, autoimmune disease, polycystic kidney disease, active diabetic retinopathy. 6) Patients who are ineligible for participating the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| comparison between changes in hemoglobin by ESA treatment and those after switching from ESA to roxadustat | — |
Secondary
| Measure | Time frame |
|---|---|
| comparison between changes in biomarkers of iron metabolism by ESA treatment and those after switching from ESA to roxadustat | — |
Countries
Japan
Contacts
Public ContactHirokazu Honda
Showa University Department of Medicine, Division of Nephrology, School of Medicine
Outcome results
None listed